Pyxis Oncology, Inc.
PYXS
$1.84
-$1.53-45.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -69.27% | -62.64% | -64.75% | -4.80% | 39.17% |
| Total Depreciation and Amortization | -30.69% | -18.74% | -15.25% | 54.75% | 118.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 273.30% | 177.32% | 141.27% | 122.34% | -66.80% |
| Change in Net Operating Assets | -1.34% | 18.35% | 125.20% | -1.36% | -74.38% |
| Cash from Operations | -34.92% | -30.41% | 7.87% | 18.44% | 26.37% |
| Capital Expenditure | 96.20% | 100.00% | 100.00% | 96.48% | 97.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -99.98% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 961.68% | 817.07% | 251.38% | 108.01% | 93.01% |
| Cash from Investing | 937.00% | 3,508.50% | 277.31% | 107.78% | 92.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -97.15% | -97.17% | 833.73% | 838.13% |
| Repurchase of Common Stock | -2,546.23% | -1,028.65% | -1,100.62% | -1,673.03% | 25.70% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.04% | -97.15% | -97.14% | 900.61% | 895.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.98% | -1,640.41% | 39.39% | 105.78% | 98.55% |